| Drug Type Monoclonal antibody | 
| Synonyms ICT 23, ICT-23 | 
| Target | 
| Action inhibitors | 
| Mechanism BTN2A1 inhibitors(Butyrophilin subfamily 2 member A1 inhibitors), BTN2A2 inhibitors(Butyrophilin subfamily 2 member A2 inhibitors) | 
| Therapeutic Areas | 
| Active Indication- | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization- | 
| Inactive Organization | 
| License Organization- | 
| Drug Highest PhaseDiscontinuedPreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Autoimmune Diseases | Preclinical | France  | - | 






